GE Healthcare has opened its first health tech startup campus at its Finland headquarters in Helsinki. It's already home to 20 health tech startups working on wireless technologies, sensors, apps and cloud services to improve healthcare.
John Dineen has already found a posh new gig only a few weeks after his departure from GE Healthcare as its newpresident and CEO was announced. He will join private equity firm Clayton, Dubilier & Rice (CD&R) early next year as an operating adviser to its funds.
Deerfield Management is looking to back a startup that's cornering about one-quarter of the world's supply of a radioisotope commonly used to create diagnostic imaging agents, molybdenum-99 (moly-99). The firm has backed Shine Medical Technologies, which has a novel technology to produce this material, with up to $125 million in debt and equity to build a manufacturing plant in Wisconsin.
GE has appointed John Flannery as the president and CEO of GE Healthcare. He was previously the SVP of business development at the company. The move comes after the healthcare division shrank a bit during the first half.
GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with GE Healthcare to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.
iHealth is not new to the mobile health device game. Launched in 2010, as a subsidiary of medical device manufacturer Andon Health--it markets several mobile-compatible devices including blood pressure and blood glucose monitors. In fact, iHealth had the first health device carried in Apple retail stores.
Both GE Healthcare and the FBI are accusing a Chinese engineer of stealing millions of files of trade secrets from a maker of magnetic resonance imaging machines and related diagnostic equipment.
GE Healthcare Life Sciences will locate its new U.S. headquarters in Marlborough, MA, hire at least 220 people and staff the facility with 500 employees.
The argument for the importance of patient diagnosis often relies upon the efficacy of subsequent treatment. But according to a recent study, three-quarters of people would want to know if they have a particular neurological disorder even if it had no cure.
Biocept is bringing on a veteran GE Healthcare and Quest Diagnostics executive to guide the company's insurance reimbursement and medical contract strategy.